Display options
Cite
Antonova LV, Krivkina EO, Rezvova MA, et al. A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses. Sovrem Tekhnologii Med. 2020;12(6):6-12doi: 10.17691/stm2020.12.6.01.
Antonova, L. V., Krivkina, E. O., Rezvova, M. A., Sevostyanova, V. V., Tkachenko, V. O., Glushkova, T. V., Akentyeva, T. N., Kudryavtseva, Y. A., & Barbarash, L. S. (2021). A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses. Sovremennye tekhnologii v meditsine, 12(6), 6-12. https://doi.org/10.17691/stm2020.12.6.01
Antonova, L V, et al. "A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses." Sovremennye tekhnologii v meditsine vol. 12,6 (2021): 6-12. doi: https://doi.org/10.17691/stm2020.12.6.01
Antonova LV, Krivkina EO, Rezvova MA, Sevostyanova VV, Tkachenko VO, Glushkova TV, Akentyeva TN, Kudryavtseva YA, Barbarash LS. A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses. Sovrem Tekhnologii Med. 2021;12(6):6-12. doi: 10.17691/stm2020.12.6.01. Epub 2020 Dec 28. PMID: 34796013; PMCID: PMC8596239.
Copy Download .nbib Format: NLM
Share it on

Sovrem Tekhnologii Med. 2021;12(6):6-12. doi: 10.17691/stm2020.12.6.01. Epub 2020 Dec 28.

A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses.

Sovremennye tekhnologii v meditsine

L V Antonova, E O Krivkina, M A Rezvova, V V Sevostyanova, V O Tkachenko, T V Glushkova, T N Akentyeva, Yu A Kudryavtseva, L S Barbarash

Affiliations

  1. Head of the Laboratory of Cell Technologies, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  2. Junior Researcher, Laboratory of Cell Technologies, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  3. Junior Researcher, Laboratory of New Biomaterials, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  4. Researcher, Laboratory of Cell Technologies, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  5. Senior Researcher; Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, 11 Acad. Lavrentieva Avenue, Novosibirsk, 630090, Russia.
  6. Researcher, Laboratory of New Biomaterials, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  7. Head of the Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
  8. Professor, Academician of the Russian Academy of Sciences, Chief Researcher Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.

PMID: 34796013 PMCID: PMC8596239 DOI: 10.17691/stm2020.12.6.01

Abstract

MATERIALS AND METHODS: Vascular prostheses from polyhydroxybutyrate/valerate and polycaprolactone with the incorporated vascular endothelial growth factor, the main fibroblast growth factor, and the chemoattractant SDF-1α were made by emulsion electrospinning. Additional surface modification of the prostheses was carried out by forming a hydrogel coating of polyvinylpyrrolidone capable of binding drugs as a result of complexation. Unfractionated heparin and iloprost were used as anti-thrombogenic drugs.

RESULTS: We show that after the modification of vascular prostheses with heparin and iloprost, a 5.8-fold increase in the Young's modulus value was noted, which indicated a greater stiffness of these grafts compared to the unmodified controls. Platelet aggregation on the surface of heparin + iloprost coated vascular prostheses was 3.3 times less than that with the unmodified controls, and 1.8 times less compared to intact platelet-rich plasma. The surface of vascular prostheses with heparin and iloprost was resistant to adhesion of platelets and blood proteins.

CONCLUSION: Drug (unfractionated heparin and iloprost) coating of the surface of biodegradable prostheses significantly improved the anti-thrombogenic properties of these grafts but contributed to the increased stiffness of the prostheses.

Keywords: anti-thrombogenic drug coating; biodegradable vascular prostheses; hemocompatibility; small-diameter grafts

Conflict of interest statement

Conflict of interest. The authors declare no conflicts of interest.

References

  1. Transl Pediatr. 2018 Apr;7(2):188-195 - PubMed
  2. Clin Hemorheol Microcirc. 2013;53(1-2):97-115 - PubMed
  3. Biomed Mater Eng. 2014;24(6):2361-9 - PubMed
  4. J Biomater Sci Polym Ed. 2015;26(8):497-514 - PubMed
  5. Regen Biomater. 2018 Mar;5(2):105-114 - PubMed
  6. Colloids Surf B Biointerfaces. 2016 May 1;141:602-610 - PubMed
  7. Int J Surg. 2017 Aug;44:244-249 - PubMed
  8. Colloids Surf B Biointerfaces. 2019 Sep 1;181:963-972 - PubMed
  9. Tissue Eng Part B Rev. 2016 Feb;22(1):68-100 - PubMed
  10. J Vasc Surg. 2016 Sep;64(3):638-47 - PubMed
  11. J Vasc Surg. 2004 Nov;40(5):924-31 - PubMed
  12. Chem Soc Rev. 2015 Aug 7;44(15):5680-742 - PubMed
  13. Vascular. 2015 Aug;23(4):358-65 - PubMed

Publication Types